Funded Project Details - FY2021
|Title:|| Targeting Integrins in Lung Cancer|
|Congressional District Code:
||Biomedical Laboratory R&D
|| February 2021 -
|FY 2021 Funding Amount:
|Total Award Amount
View full abstract and other project information on NIH RePORTER
Go To NIH RePORTER
Lung cancer is the most common cause of cancer-related deaths in US veterans and worldwide. Molecularly targeted therapy and immunotherapy are two recent major breakthroughs in lung cancer treatment that have been shown to extend life and increase cure, but each of them benefits ~20% of non-small cell lung cancer (NSCLC) patients. Novel therapeutic strategies are needed to identify new treatment targets and develop and validate the assays that select the appropriate patients for molecularly targ...
Questions about the R&D website? Email the Web Team
Any health information on this website is strictly for informational purposes and is not intended as medical advice. It should not be used to diagnose or treat any condition.